Table 1.

Baseline characteristics of the study populationa

Characteristic% CompleteCalcitriol Users (n = 429)Matched Controls (n = 989)
Demographics
Age10069.0 ± 10.370.3 ± 10.3
Male100420 (97.9)974 (98.5)
Race71
    white263 (85.1)598 (86.4)
    black36 (11.7)70 (10.1)
    other10 (3.2)24 (3.5)
Comorbidityb
    diabetes100276 (64.3)581 (58.7)
    coronary heart disease10090 (21.0)170 (17.2)
    peripheral vascular disease100112 (26.1)285 (28.8)
Charlson comorbidity indexc1004.7 ± 2.04.5 ± 2.1
eGFR10031.1 ± 9.232.8 ± 10.4
Baseline medication use
    cholecalciferol or ergocalciferol10035 (8.2)86 (8.7)
    oral calcium100118 (27.5)179 (18.1)
    epoetin or darbepoetin10065 (15.2)131 (13.2)
    statin100290 (67.6)579 (58.5)
    ACEI or ARB100267 (62.2)564 (57.0)
Body mass indexd9831.0 ± 6.430.5 ± 6.6
Systolic BP (mm/Hg)d98142.1 ± 17.2140.7 ± 17.9
Laboratory valuesd
    creatinine (mg/dL)1002.6 ± 0.82.5 ± 0.8
    albumin (g/L)943.9 ± 0.43.9 ± 0.4
    hemoglobin (g/L)9912.5 ± 1.712.6 ± 1.8
    calcium (mg/dL)1008.9 ± 0.69.1 ± 0.5
    phosphate (mg/dL)993.8 ± 0.83.8 ± 0.8
    PTH (pg/dL)100231.0 ± 127.2145.1 ± 91.7
Health care use
Nephrology visits during previous year1002.8 ± 1.92.3 ± 1.8
eGFR at nephrology referral9736.4 ± 17.036.3 ± 14.7
Prostate specific antigen screening (% of men)10071 (17.4)190 (19.9)
Metropolitan VA Site100346 (80.7)766 (77.5)
  • a Data are means ± SD or n (%). ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

  • b Comorbidity assessed using all previous medical information before the study start date.

  • c Charlson comorbidity index calculated using hospitalization data from the previous year.

  • d Outpatient measurements time averaged during the year before the study start date.